What Aerovate Therapeutics does

Aerovate Therapeutics was a clinical-stage biopharmaceutical company founded in 2020 in Boston, Massachusetts and originally focused on developing therapies for pulmonary arterial hypertension. The company completed its initial public offering in 2022 and traded on NASDAQ under the ticker AVTE. Its underlying technology centered on antibody-based therapeutics developed through Paragon Therapeutics' antibody discovery engine, founded by Fairmount. Following an April 2025 merger with Jade Biosciences — accompanied by a private placement of approximately $300 million — Aerovate ceased operating as an independent public company and became part of the combined entity operating under Jade Biosciences.

The combined company redirected its therapeutic focus to autoimmune diseases. Its lead clinical candidate, JADE101, is designed to inhibit the cytokine APRIL (A PRoliferation-Inducing Ligand) and is being developed for immunoglobulin A nephropathy (IgAN), with JADE-001 slated to enter clinical trials in late 2025. Both programs build on discovery-stage assets licensed from Paragon Therapeutics.

Aerovate had 11–50 employees, generated no commercial revenue (clinical-stage, pre-commercial), and was funded by a ~$75 million Series A in 2021 and the ~$300 million 2025 private placement. Its intended go-to-market model upon approval relies on pharmaceutical distribution networks and specialty pharmacy channels for biologic injectable therapies. Following the merger, Aerovate is functionally a subsidiary of Jade Biosciences, and standalone Aerovate metrics no longer apply.

Name

Aerovate Therapeutics

Legal name

Aerovate Therapeutics Inc.

Website

https://aerovatetx.com

Company type

Public

Founded year

2020

Operating status

Acquired

Headcount range

11–50 employees

Short description

Aerovate Therapeutics was a Boston-based clinical-stage biopharmaceutical company that developed antibody-based therapies, originally for pulmonary arterial hypertension and, following its April 2025 merger into Jade Biosciences, for autoimmune diseases including IgAN.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Rare cardiopulmonary disease
• Biopharmaceutical development
• Autoimmune disease therapeutics
• Antibody-based biologics
• Clinical-stage biotechnology

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pharmaceutical development and commercialization: The combined company following the merger between Jade Biosciences and Aerovate Therapeutics plans to advance therapies for autoimmune diseases through clinical development and eventual commercialization of drug candidates.

Distribution channels1 record

Marketing channels3 records

Core offering

Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for rare cardiopulmonary and autoimmune diseases. Following its April 2025 merger with Jade Biosciences, the combined entity is advancing lead candidate JADE101, an APRIL cytokine inhibitor for immunoglobulin A nephropathy (IgAN), and JADE-001, entering clinical trials in late 2025. Programs are built on discovery-stage assets licensed from Paragon Therapeutics' antibody discovery engine.

Product overview

Jade Biosciences, the entity resulting from the merger with Aerovate Therapeutics (April 2025), is a clinical-stage company developing a pipeline of potentially best-in-class therapies aimed at transforming the standard of care for patients living with autoimmune diseases. The company's lead candidates include JADE101 (designed to inhibit APRIL cytokine for IgAN) and JADE-001 (entering clinical trials in late 2025 for autoimmune diseases). The programs build on discovery-stage assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. Note: Aerovate Therapeutics (NASDAQ:AVTE) was acquired by Jade Biosciences and no longer operates as an independent entity.

Differentiator

Problem solved

Functional benefit

Products and services

• JADE101

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Paragon TherapeuticscoreTechnology or IntegrationJade's programs build on discovery-stage assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. This licensing agreement provides access to proprietary antibody discovery technology for developing autoimmune disease therapies.

Scale indicators1 record

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Vertex Pharmaceuticals: Vertex is developing povetacicept (an APRIL/BAFF inhibitor) for IgAN via its acquisition of Alpine Immune Sciences, placing Vertex in direct mechanistic competition with JADE101. As a large-cap biopharma with substantial resources, Vertex represents a formidable competitor with broader autoimmune ambitions.
• Otsuka Pharmaceutical: Otsuka is developing sibeprenlimab, an APRIL-targeting antibody in IgAN, providing direct mechanistic competition to JADE101. As a large, established Japanese pharma with global commercialization capability, Otsuka represents a much larger incumbent threat in the APRIL inhibitor space.
• Argenx: Argenx is a global immunology-focused biotechnology company commercializing efgartigimod (Vyvgart) across multiple autoimmune indications. As a profitable, late-stage antibody developer in autoimmune disease, Argenx provides a benchmark for the autoimmune antibody franchise Jade is pursuing.
• Roche / Genentech: Roche has historically developed antibodies across autoimmune indications and operates a major immunology franchise. As a broad incumbent with deep biologics manufacturing and commercialization infrastructure, Roche is a relevant comparator for any autoimmune-focused antibody biotech's long-term commercial trajectory.

Direct peers

• Chinook Therapeutics: Chinook Therapeutics was a clinical-stage biotech developing therapies for IgAN and other rare kidney diseases before being acquired by Novartis for $3.5B in 2023. It serves as a relevant precedent for M&A exit valuations in the IgAN therapeutic space and a direct indication comparator.
• Travere Therapeutics: Travere Therapeutics received accelerated approval for sparsentan (Filspari) in IgAN, making it a direct competitor in the same indication. Travere serves as a relevant benchmark for the IgAN commercial landscape that JADE101 is entering.
• Vera Therapeutics: Vera Therapeutics is a late-stage clinical biotechnology company developing atacicept for IgAN — a direct APRIL/B-cell modulating competitor to Jade's JADE101. Both companies target the same mechanism and patient population, making Vera the most direct comparability benchmark for JADE101's commercial potential.

Others

• Paragon Therapeutics: Paragon Therapeutics is the antibody discovery engine founded by Fairmount that licenses assets to Jade Biosciences. As the upstream platform feeding Jade's pipeline, Paragon is an enabling/partner company critical to Jade's strategic position, though not a direct competitor.

Emerging players

• Apellis Pharmaceuticals: Apellis is a commercial-stage biopharmaceutical company developing complement inhibitors for autoimmune and ophthalmologic diseases. Apellis provides a benchmark for a clinical-to-commercial autoimmune biologics company of similar size and ambition.
• Annexon Biosciences: Annexon is a clinical-stage biotechnology company developing complement pathway inhibitors for autoimmune and neurodegenerative diseases. While targeting a different pathway, Annexon is a comparable clinical-stage autoimmune-focused antibody/biologics developer with similar capital and pipeline profile.

Market position

Strengths2 records

Weaknesses4 records

Competitive moat2 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/aerovatetx

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aerovate Therapeutics